DNAtrix is a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix’s lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, an aggressive form of brain cancer. The company’s pipeline includes viruses armed with potent immunomodulatory molecules to treat cancer. 
Technology
DNAtrix is developing potent oncolytic immunotherapies for the treatment of cancer using genetically modified viruses that maximize safety and efficacy.
learn more >
August 1, 2018TMC News: The Common Cold as Cure? Adenovirus shows promise as brain tumor immunotherapy
July 2, 2018Treatment of Pediatric Brain Tumor, DIPG, with Oncolytic Adenovirus DNX-2401 to be Presented at 2018 ISPNO
May 14, 2018The Brain Tumour Charity: Treating diffuse midline gliomas with an oncolytic virus
DNAtrix is a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix’s lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, an aggressive form of brain cancer. The company’s pipeline includes viruses armed with potent immunomodulatory molecules to treat cancer. learn more >
Pipeline
A pipeline of novel viral-driven immunotherapies is being developed for the treatment of a variety of aggressive cancers.
learn more >
For Patients
Human clinical trials of DNAtrix therapies are ongoing for patients diagnosed with glioblastoma, an aggressive form of brain cancer.
learn more >
Virus artwork by Luke Jerram